Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Read more about Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Read more about Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging. Read more about Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging.
Nicotine e-cigarettes as a tool for smoking cessation. Read more about Nicotine e-cigarettes as a tool for smoking cessation.
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Read more about Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Read more about Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Ensuring remote diagnostics for pathologists: an open letter to the US Congress. Read more about Ensuring remote diagnostics for pathologists: an open letter to the US Congress.
Advancing T cell-based cancer therapy with single-cell technologies. Read more about Advancing T cell-based cancer therapy with single-cell technologies.
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Read more about Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.
